Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Health services and systems news

Show

From To
National HIV Prevention Funding – An essential investment

The Government is reducing funding for HIV prevention by 50% from 2015. There is no indication that HIV transmission rates in England are reducing and there continue to be major gaps in public understanding of how to prevent HIV. HIV prevention funding must remain at least at current levels.

Published
12 December 2014
From
National AIDS Trust
The International AIDS Society announces Amsterdam as site of the International AIDS Conference in July 2018

Today, The International AIDS Society (IAS) announced that Amsterdam, Netherlands will host the 22nd International AIDS Conference (AIDS 2018). AIDS 2018 will be held on 22-28 July 2018 at the Amsterdam RAI and is expected to bring together some 18,000 participants from around the world.

Published
12 December 2014
From
International AIDS Society
Class Action Lawsuit Challenges Exorbitant Pricing of Gilead’s Hepatitis-C Drug Sovaldi

Gilead has been selling a twelve week regimen of Sovaldi in the United States for approximately $84,000, or $1,000 per pill. This is significantly more than the original price projection for Sovaldi, and in sharp contrast to the prices at which the drug is being made available in other countries. Gilead recently announced its intention to make Sovaldi available in 91 developing countries at deeply discounted prices, and the drug is reportedly available in Egypt for 99% below the U.S. price. This obvious pricing paradox is under investigation by the Senate Finance Committee, which has questioned if the market for Sovaldi “is working efficiently and rationally,” and whether “payors of health care….can carry such a load.”

Published
12 December 2014
From
Chimicles & Tikellis press release
How San Francisco Is Getting to Zero On HIV

San Francisco is already making progress when it comes to HIV prevention, treatment and retention. In 2006, San Francisco had 517 new HIV cases; by 2013, that number dropped to 359, a 30 percent decrease. The number of deaths almost halved between 2006 and 2013, going from 327 to 182. Additionally, compared to the United States, San Francisco is faring better in multiple aspects of the HIV care continuum: in 2012, 82 percent of HIV positive individuals in the U.S. were aware of their status; in San Francisco, that number was 94 percent.

Published
11 December 2014
From
Huffington Post
Uganda: Emphasising evidence-based prevention technologies a better deal

On World AIDS Day President Yoweri Museveni told Ugandan youth to fight AIDS by not having sex and blamed evidence-based prevention interventions, in particular, condoms and medical male circumcision on Uganda’s troubled AIDS response. He also said becoming HIV-positive brings shame to a family. These off-the-cuff comments cause more harm than good.

Published
10 December 2014
From
New Vision
Will AbbVie's 3-DA regimen prove a compelling competitor to Gilead's Harvoni?

Later this month, the FDA is expected to approve AbbVie's oral '3-DA' product - comprising Viekirax (ombitasvir/ paritaprevir/ ritonavir) plus Exviera (dasabuvir) - for the treatment of genotype 1 hepatitis C patients. European approval is expected to occur in early 2015 following a positive recommendation from a European Medicines Agency committee last month. Payers in the US are hoping that AbbVie will deliver festive cheer by announcing a notable 'sticker price' discount versus Gilead Sciences' Harvoni brand, which costs $94,500 for a 12-week supply.

Published
10 December 2014
From
Hepatitis C New Drugs
Sophisticated HIV diagnostics adapted for remote areas

Diagnosing HIV and other infectious diseases presents unique challenges in remote locations that lack electric power, refrigeration, and appropriately trained health care staff. To address these issues, researchers have developed a low-cost, electricity-free device capable of detecting the DNA of infectious pathogens, including HIV-1.

Published
10 December 2014
From
Science Daily
HIV dollars drop with waning philanthropic funds

Last year saw the lowest level of funding from charitable donors since 2007, the year when government spending on HIV began to drop. While the report notes that philanthropic support accounted for just three percent of all international funding for HIV-related efforts in low and middle-income countries, it has increasingly been cited in recent years as a source of support to fill gaps left by constricting national budgets.

Published
10 December 2014
From
Science Speaks
PEPFAR’s ‘Global Pediatric ARV Commitment-To-Action’ Aims To Improve Drug Access

Since the start of President Obama’s Administration, the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) has achieved a four-fold increase and is now providing 7.7 million people with life-saving antiretroviral (ARV) treatment worldwide. Despite this, only 1 in 4 of the 3.2 million children living with HIV/AIDS worldwide are today receiving treatment.

Published
09 December 2014
From
US Department of State
The Most Celebrated, Mistrusted Little Pill in the World

AIDS activists Sean Strub and Peter Staley have been in opposite camps for the past several years. This was the first time the pair had met face to face to discuss PrEP, and their conversation was intense, passionate and sometimes stinging. The men love each other dearly, and yet they, too, have been swept up in the controversy.

Published
07 December 2014
From
Huffington Post

Filter by country